Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity

The Vice President, Head of Transactions and Partnering is a senior leader within the Corporate Development organization and will play a key role in the evaluation, structuring, negotiation, and execution of strategic business development transactions that support Revolution Medicines’ corporate and portfolio objectives. Reporting to the Head of Corp Development, this individual is a leader and principal negotiator across licensing, collaboration, co-development, alliance, option, platform, and other business development agreements. The role partners closely with executive leadership and stakeholders across Research, Development, Commercial, Finance, Legal, Intellectual Property, and Executive Management to shape strategy and advance high-priority opportunities from initial assessment through execution.

The successful candidate will bring deep transaction expertise, strong business judgment, exceptional negotiation skills, and demonstrated people leadership. This role will lead a high-performing transactions and partnering team with the capabilities, operating model, and culture to support evolving strategic priorities; attract, develop, empower, and retain exceptional talent; and establish clear roles, standards, and ways of working. Through a culture of collaboration, accountability, learning, and excellence, they will help establish and execute partnerships that accelerate innovation, expand capabilities, and create long-term value for patients and shareholders.

Responsibilities

Transaction Leadership and Execution

Lead transaction activities, advancing prioritized opportunities from evaluation through execution while ensuring resources are focused on the highest-value opportunities.

Serve as the senior transaction lead for the most complex and strategically significant business development opportunities, while developing and empowering team members to lead transactions with increasing scope and independence.

Structure, negotiate, and execute a broad range of transactions, including licensing, collaboration, co-development, alliance, option, platform, and other strategic agreements.

Lead transaction processes from initial engagement through confidentiality agreements, term sheet development, definitive agreement negotiation, and transaction closing.

Develop creative transaction structures that appropriately balance strategic objectives, economics, operational considerations, and risk allocation.

Identify transaction risks and develop practical solutions that facilitate successful deal execution while protecting the company's interests.

Negotiation and Deal Structuring

Serve as Revolution Medicines' senior negotiator for strategic business development transactions and establish a consistent, high-quality approach to negotiation across the transactions team.

Partner closely with finance and legal/transaction counsel to develop transaction structures, review and negotiate definitive agreements, and drive successful deal execution.

Collaborate with FP&A, commercial, competitive intelligence, business development team members to evaluate transaction economics, valuation analyses, and investment considerations.

Lead negotiations involving scientific, clinical, commercial, intellectual property, operational, and financial elements of complex transactions.